Ahead of In Vivo’s 2024 Rising Leaders list being revealed in April, a panel of biopharma leaders discussed industry trends and biopharma career stories at BIO-Europe Spring.

Nucleic acid-based therapies are poised to revolutionize medicine – just as antibodies did thirty years ago.

Lilly looks To Elektrofi for help on subcutaneous injectable therapies, while NAYA will merge with INVO and acquire two antibodies from Cytovia. Plus deals involving Hummingbird/Endeavor, Basilea/Gravitas/Intron, Lilly/Mablink and Sotio/Synaffix.

From an early stage in his career, Miquel Vila-Perelló saw himself as a research academic. It was an ambition he duly fulfilled. Later, seeing the greater potential to bring benefit to human health by forming his own company, he co-founded SpliceBio, a Spain-based startup focusing on gene therapies for rare diseases.